Cardiovascular Disease Medicare Stents 
DAIC
JUNE 12, 2024
and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. It is the third most common cardiovascular disease [2]. For long lesions, Duo Extend smoothly overlaps with the Duo Hybrid to extend therapy.
DAIC
MARCH 28, 2025
v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronary artery disease (CAD), making it a valuable tool for clinicians.
DAIC
JUNE 18, 2024
FDA Breakthrough Device Designation accelerates the review process for novel technologies that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as CAD, which impacts 7.8% Stent Related Adverse Events greater than 1 Year After PCI. of the U.S. population.
American College of Cardiology
FEBRUARY 1, 2025
Initiatives such as the World Health Organization's "Medication Without Harm" and the Centers for Medicare and Medicaid Services' (CMS) expanded quality measures aim to reduce preventable emergency visits and hospital admissions due to medication-related harm. All are members of ACC’s Cardiovascular Team Member Section.
Dr. S. Venkatesan MD
JANUARY 1, 2025
It is asking for stenting all non-flow limiting lesion , if found, to carry high risk plaques by intracoronary Imaging. Top 10 Clinical Trials Preventive PCI on Stenosis With Functionally Insignificant Vulnerable Plaque PREVENT (ACC.24) 24) Microaxial Flow Pump in Infarct-Related Cardiogenic Shock DanGer Shock (ACC.24) Did we follow up ?
Expert insights. Personalized for you.
105 
Let's personalize your content